Report Detail
Global GLP-1 Peptide Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
- RnM4587663 |
- 21 May, 2024 |
- Global |
- 91 Pages |
- GIR (Global Info Research) |
- Other
Glucagon-likepeptide-1 (GLP-1) is a hormone secreted by intestinal L cells. Its receptor (GLP-1R) is widely distributed in the central nervous system, cardiovascular system, muscles, and gastrointestinal tract. multiple organs and tissues. GLP-1 has glucose concentration-dependent hypoglycemic effects, and its receptor agonist (GLP-1RA) can simulate the physiological effects of GLP-1 and is an important drug for the treatment of diabetes and obesity. In addition, GLP-1RA also has protective effects on the cardiovascular system, kidneys, central nervous system, etc.
GLP-1 peptide drugs are often used to treat patients with type 2 diabetes. They can control blood sugar while also bringing weight loss and reducing cardiovascular risk.
According to our (Global Info Research) latest study, the global GLP-1 Peptide Drugs market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global GLP-1 Peptide Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global GLP-1 Peptide Drugs market size and forecasts, in consumption value ($ Million), 2019-2030
Global GLP-1 Peptide Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global GLP-1 Peptide Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global GLP-1 Peptide Drugs market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1 Peptide Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1 Peptide Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Novo Nordisk, Sanofi, GSK, Eli Lilly, Benemae Pharmaceutical, Hansoh Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
GLP-1 Peptide Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
GLP-1 Peptide Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Injection
Oral
Market segment by Application
Type 2 Diabetes
Obesity
Others
Market segment by players, this report covers
AstraZeneca
Novo Nordisk
Sanofi
GSK
Eli Lilly
Benemae Pharmaceutical
Hansoh Pharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe GLP-1 Peptide Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of GLP-1 Peptide Drugs, with revenue, gross margin, and global market share of GLP-1 Peptide Drugs from 2019 to 2024.
Chapter 3, the GLP-1 Peptide Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and GLP-1 Peptide Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of GLP-1 Peptide Drugs.
Chapter 13, to describe GLP-1 Peptide Drugs research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of GLP-1 Peptide Drugs by Type
- 1.3.1 Overview: Global GLP-1 Peptide Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global GLP-1 Peptide Drugs Consumption Value Market Share by Type in 2023
- 1.3.3 Injection
- 1.3.4 Oral
- 1.4 Global GLP-1 Peptide Drugs Market by Application
- 1.4.1 Overview: Global GLP-1 Peptide Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Type 2 Diabetes
- 1.4.3 Obesity
- 1.4.4 Others
- 1.5 Global GLP-1 Peptide Drugs Market Size & Forecast
- 1.6 Global GLP-1 Peptide Drugs Market Size and Forecast by Region
- 1.6.1 Global GLP-1 Peptide Drugs Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global GLP-1 Peptide Drugs Market Size by Region, (2019-2030)
- 1.6.3 North America GLP-1 Peptide Drugs Market Size and Prospect (2019-2030)
- 1.6.4 Europe GLP-1 Peptide Drugs Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific GLP-1 Peptide Drugs Market Size and Prospect (2019-2030)
- 1.6.6 South America GLP-1 Peptide Drugs Market Size and Prospect (2019-2030)
- 1.6.7 Middle East & Africa GLP-1 Peptide Drugs Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 AstraZeneca
- 2.1.1 AstraZeneca Details
- 2.1.2 AstraZeneca Major Business
- 2.1.3 AstraZeneca GLP-1 Peptide Drugs Product and Solutions
- 2.1.4 AstraZeneca GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 AstraZeneca Recent Developments and Future Plans
- 2.2 Novo Nordisk
- 2.2.1 Novo Nordisk Details
- 2.2.2 Novo Nordisk Major Business
- 2.2.3 Novo Nordisk GLP-1 Peptide Drugs Product and Solutions
- 2.2.4 Novo Nordisk GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Novo Nordisk Recent Developments and Future Plans
- 2.3 Sanofi
- 2.3.1 Sanofi Details
- 2.3.2 Sanofi Major Business
- 2.3.3 Sanofi GLP-1 Peptide Drugs Product and Solutions
- 2.3.4 Sanofi GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Sanofi Recent Developments and Future Plans
- 2.4 GSK
- 2.4.1 GSK Details
- 2.4.2 GSK Major Business
- 2.4.3 GSK GLP-1 Peptide Drugs Product and Solutions
- 2.4.4 GSK GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 GSK Recent Developments and Future Plans
- 2.5 Eli Lilly
- 2.5.1 Eli Lilly Details
- 2.5.2 Eli Lilly Major Business
- 2.5.3 Eli Lilly GLP-1 Peptide Drugs Product and Solutions
- 2.5.4 Eli Lilly GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Eli Lilly Recent Developments and Future Plans
- 2.6 Benemae Pharmaceutical
- 2.6.1 Benemae Pharmaceutical Details
- 2.6.2 Benemae Pharmaceutical Major Business
- 2.6.3 Benemae Pharmaceutical GLP-1 Peptide Drugs Product and Solutions
- 2.6.4 Benemae Pharmaceutical GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Benemae Pharmaceutical Recent Developments and Future Plans
- 2.7 Hansoh Pharmaceutical
- 2.7.1 Hansoh Pharmaceutical Details
- 2.7.2 Hansoh Pharmaceutical Major Business
- 2.7.3 Hansoh Pharmaceutical GLP-1 Peptide Drugs Product and Solutions
- 2.7.4 Hansoh Pharmaceutical GLP-1 Peptide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Hansoh Pharmaceutical Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global GLP-1 Peptide Drugs Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of GLP-1 Peptide Drugs by Company Revenue
- 3.2.2 Top 3 GLP-1 Peptide Drugs Players Market Share in 2023
- 3.2.3 Top 6 GLP-1 Peptide Drugs Players Market Share in 2023
- 3.3 GLP-1 Peptide Drugs Market: Overall Company Footprint Analysis
- 3.3.1 GLP-1 Peptide Drugs Market: Region Footprint
- 3.3.2 GLP-1 Peptide Drugs Market: Company Product Type Footprint
- 3.3.3 GLP-1 Peptide Drugs Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global GLP-1 Peptide Drugs Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global GLP-1 Peptide Drugs Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global GLP-1 Peptide Drugs Consumption Value Market Share by Application (2019-2024)
- 5.2 Global GLP-1 Peptide Drugs Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America GLP-1 Peptide Drugs Consumption Value by Type (2019-2030)
- 6.2 North America GLP-1 Peptide Drugs Market Size by Application (2019-2030)
- 6.3 North America GLP-1 Peptide Drugs Market Size by Country
- 6.3.1 North America GLP-1 Peptide Drugs Consumption Value by Country (2019-2030)
- 6.3.2 United States GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 6.3.3 Canada GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 6.3.4 Mexico GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe GLP-1 Peptide Drugs Consumption Value by Type (2019-2030)
- 7.2 Europe GLP-1 Peptide Drugs Consumption Value by Application (2019-2030)
- 7.3 Europe GLP-1 Peptide Drugs Market Size by Country
- 7.3.1 Europe GLP-1 Peptide Drugs Consumption Value by Country (2019-2030)
- 7.3.2 Germany GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 7.3.3 France GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 7.3.5 Russia GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 7.3.6 Italy GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific GLP-1 Peptide Drugs Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific GLP-1 Peptide Drugs Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific GLP-1 Peptide Drugs Market Size by Region
- 8.3.1 Asia-Pacific GLP-1 Peptide Drugs Consumption Value by Region (2019-2030)
- 8.3.2 China GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 8.3.3 Japan GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 8.3.4 South Korea GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 8.3.5 India GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 8.3.7 Australia GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America GLP-1 Peptide Drugs Consumption Value by Type (2019-2030)
- 9.2 South America GLP-1 Peptide Drugs Consumption Value by Application (2019-2030)
- 9.3 South America GLP-1 Peptide Drugs Market Size by Country
- 9.3.1 South America GLP-1 Peptide Drugs Consumption Value by Country (2019-2030)
- 9.3.2 Brazil GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 9.3.3 Argentina GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa GLP-1 Peptide Drugs Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa GLP-1 Peptide Drugs Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa GLP-1 Peptide Drugs Market Size by Country
- 10.3.1 Middle East & Africa GLP-1 Peptide Drugs Consumption Value by Country (2019-2030)
- 10.3.2 Turkey GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
- 10.3.4 UAE GLP-1 Peptide Drugs Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 GLP-1 Peptide Drugs Market Drivers
- 11.2 GLP-1 Peptide Drugs Market Restraints
- 11.3 GLP-1 Peptide Drugs Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 GLP-1 Peptide Drugs Industry Chain
- 12.2 GLP-1 Peptide Drugs Upstream Analysis
- 12.3 GLP-1 Peptide Drugs Midstream Analysis
- 12.4 GLP-1 Peptide Drugs Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on GLP-1 Peptide Drugs. Industry analysis & Market Report on GLP-1 Peptide Drugs is a syndicated market report, published as Global GLP-1 Peptide Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of GLP-1 Peptide Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
